Chung KF, Wenzel SE, Brozek JL et al (2014) International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43(2):343–373
Article CAS PubMed Google Scholar
Wang E, Wechsler ME, Tran TN et al (2020) Characterization of severe asthma worldwide: data from the international severe asthma registry. Chest 157(4):790–804
Article CAS PubMed Google Scholar
Calzetta L, Matera MG, Rogliani P (2019) Monoclonal antibodies in severe asthma: is it worth it? Expert Opin Drug Metab Toxicol 15(6):517–520
Rogliani P, Calzetta L, Matera MG et al (2020) Severe asthma and biological therapy: when, which, and for whom. Pulm Ther 6(1):47–66
Soendergaard MB, Hansen S, Bjerrum AS et al (2022) Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register. ERJ Open Res. https://doi.org/10.1183/23120541.00238-2022
Article PubMed PubMed Central Google Scholar
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention; 2019. https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Accessed 23 Feb 2023
Ortega H, Yancey SW, Keene ON et al (2018) Asthma exacerbations associated with lung function decline in patients with severe eosinophilic asthma. J Allergy Clin Immunol Pract 6(3):980-986 e1
Newby C, Agbetile J, Hargadon B et al (2014) Lung function decline and variable airway inflammatory pattern: longitudinal analysis of severe asthma. J Allergy Clin Immunol 134(2):287–294
Castro M, Rabe KF, Corren J et al (2020) Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. ERJ Open Res. https://doi.org/10.1183/23120541.00204-2019
Article PubMed PubMed Central Google Scholar
Castro M, Zangrilli J, Wechsler ME et al (2015) Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3(5):355–366
Article CAS PubMed Google Scholar
Ortega HG, Liu MC, Pavord ID et al (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371(13):1198–1207
Rabe KF, Nair P, Brusselle G et al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378(26):2475–2485
Article CAS PubMed Google Scholar
Wenzel S, Castro M, Corren J et al (2016) Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 388(10039):31–44
Article CAS PubMed Google Scholar
Lee JHDP, Dixey P, Bhavsar P et al (2023) Precision Medicine Intervention in Severe Asthma (PRISM) study: molecular phenotyping of patients with severe asthma and response to biologics. ERJ Open Res 9(2):00485–02022
Article PubMed PubMed Central Google Scholar
Reddel HK, Taylor DR, Bateman ED et al (2009) An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 180(1):59–99
NCT05164939, Precision Medicine Intervention in Severe Asthma (PRISM) Study. clinicaltrials.gov/ct2/show/NCT05164939. Accessed 21 Dec 2021
Perez de Llano L, Davila I, Martinez-Moragon E et al (2021) Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: The FEV(1), exacerbations, oral corticosteroids, symptoms score. J Allergy Clin Immunol Pract 9(7):2725–2731
Article CAS PubMed Google Scholar
Lopez-Raton M, Cadarso-Suarez C, Rodriguez-Alvarez MX et al (2014) OptimalCutpoints: an R package for selecting optimal cutpoints in diagnostic tests. J Stat Softw 61(8):1–36
Ortega HG, Yancey SW, Mayer B et al (2016) Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 4(7):549–556
Article CAS PubMed Google Scholar
Shrimanker R, Keene O, Hynes G et al (2019) Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis. Am J Respir Crit Care Med 200(10):1308–1312
Article CAS PubMed Google Scholar
Bleecker ER, Wechsler ME, FitzGerald JM et al (2018) Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J 52(4):1800936
Article PubMed PubMed Central Google Scholar
Brusselle G, Germinaro M, Weiss S et al (2017) Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm Pharmacol Ther 43:39–45
Article CAS PubMed Google Scholar
FitzGerald JM, Bleecker ER, Menzies-Gow A et al (2018) Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med 6(1):51–64
Article CAS PubMed Google Scholar
Buhl R, Humbert M, Bjermer L et al (2017) Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J 49(5):1700634
Kwon JW, Jung H, Kim SH et al (2019) High ACT score is not sufficient to reduce the risk of asthma exacerbations in asthma with low lung function. Respir Med 150:38–44
Kroes JA, Zielhuis SW, van Roon EN et al (2020) Prediction of response to biological treatment with monoclonal antibodies in severe asthma. Biochem Pharmacol 179:113978
Article CAS PubMed Google Scholar
Nathan RA, Sorkness CA, Kosinski M et al (2004) Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 113(1):59–65
van Dijk BCP, Svedsater H, Heddini A et al (2020) Relationship between the Asthma Control Test (ACT) and other outcomes: a targeted literature review. BMC Pulm Med 20(1):79
Comments (0)